Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 12, 2013, Pages 2740-2749

  Vaiyapuri, Sakthivel ^a   Ali, Marfoua S ^a   Moraes, Leonardo A ^a   Sage, Tanya ^a   Lewis, Kirsty R ^a   Jones, Chris I ^a   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Blood platelets; cAMP; cGMP; Tangeretin; Thrombosis

Indexed keywords

CALCIUM; CYCLIC GMP; CYCLIC NUCLEOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TANGERETIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; VERY LATE ACTIVATION ANTIGEN 2;

ARTICLE; BLEEDING TIME; BLOOD CLOT RETRACTION; BLOOD CLOTTING; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HEMOSTASIS; HOMEOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; CAMP; CGMP; TANGERETIN; THROMBOSIS;

ANIMALS; BLOOD PLATELETS; CALCIUM SIGNALING; CELL ADHESION MOLECULES; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONES; HEMOSTASIS; HUMANS; MICE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SECOND MESSENGER SYSTEMS; THROMBOSIS; TIME FACTORS;

EID: 84888200706     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301988     Document Type: Article

References (58)

1. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci. 2004;117(pt 16):3415-3425
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695
3. Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451:914-918
4. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, Sage T, Stanley RG, Tucker KL, Wright B, Gibbins JM. Future innovations in anti-platelet therapies. Br J Pharmacol. 2008;154:918-939
5. Michelson AD. P2Y12 antagonism: Promises and challenges. Arterioscler Thromb Vasc Biol. 2008;28:s33-s38
6. Wright B, Spencer JP, Lovegrove JA, Gibbins JM. Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs. Cardiovasc Res. 2013;97:13-22
7. Middleton E Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000;52:673-751
8. Benavente-García O, Castillo J. Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem. 2008;56:6185-6205
9. Hubbard GP, Wolffram S, de Vos R, Bovy A, Gibbins JM, Lovegrove JA. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: A pilot study. Br J Nutr. 2006;96:482-488
10. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: A systematic review and meta-Analysis of randomized trials. Am J Clin Nutr. 2012;95:740-751
11. Wright B, Moraes LA, Kemp CF, Mullen W, Crozier A, Lovegrove JA, Gibbins JM. A structural basis for the inhibition of collagen-stimulated platelet function by quercetin and structurally related flavonoids. Br J Pharmacol. 2010;159:1312-1325
12. Hubbard GP, Stevens JM, Cicmil M, Sage T, Jordan PA, Williams CM, Lovegrove JA, Gibbins JM. Quercetin inhibits collagen-stimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost. 2003;1:1079-1088
13. Lill G, Voit S, Schrör K, Weber AA. Complex effects of different green tea catechins on human platelets. FEBS Lett. 2003;546:265-270
14. Tominari T, Hirata M, Matsumoto C, Inada M, Miyaura C. Polymethoxy flavonoids, nobiletin and tangeretin, prevent lipopolysaccharide-induced inflammatory bone loss in an experimental model for periodontitis. J Pharmacol Sci. 2012;119:390-394
15. Kim MS, Hur HJ, Kwon DY, Hwang JT. Tangeretin stimulates glucose uptake via regulation of AMPK signaling pathways in C2C12 myotubes and improves glucose tolerance in high-fat diet-induced obese mice. Mol Cell Endocrinol. 2012;358:127-134
16. Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids. 2004;39:143-151
17. Arafa el-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, Wani AA. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway. Cancer Res. 2009;69:8910-8917
18. Chaumontet C, Bex V, Gaillard-Sanchez I, Seillan-Heberden C, Suschetet M, Martel P. Apigenin and tangeretin enhance gap junctional intercellular communication in rat liver epithelial cells. Carcinogenesis. 1994;15:2325-2330
19. Chaumontet C, Droumaguet C, Bex V, Heberden C, Gaillard-Sanchez I, Martel P. Flavonoids (apigenin, tangeretin) counteract tumor promoterinduced inhibition of intercellular communication of rat liver epithelial cells. Cancer Lett. 1997;114:207-210
20. Seo J, Lee HS, Ryoo S, Seo JH, Min BS, Lee JH. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation. Eur J Pharmacol. 2011;673:56-64
21. Benavente-Garća O CJ, Marin FR, Ortun A, Del Río JA. Uses and properties of citrus flavonoids. J Agric Food Chem. 1997;45:4505-4515
22. Manthey JA, Cesar TB, Jackson E, Mertens-Talcott S. Pharmacokinetic study of nobiletin and tangeretin in rat serum by high-performance liquid chromatography-electrospray ionization-mass spectrometry. J Agric Food Chem. 2011;59:145-151
23. Calderwood DA. Integrin activation. J Cell Sci. 2004;117(pt 5):657-666
24. Hathaway DR, Adelstein RS. Human platelet myosin light chain kinase requires the calcium-binding protein calmodulin for activity. Proc Natl Acad Sci U S A. 1979;76:1653-1657
25. Shattil SJ, Brass LF. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987;262:992-1000
26. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4: 517-529
27. Ok WJ, Cho HJ, Kim HH, Lee DH, Kang HY, Kwon HW, Rhee MH, Kim M, Park HJ. Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. J Atheroscler Thromb. 2012;19: 337-348
28. Li Z, Ajdic J, Eigenthaler M, Du X. A predominant role for cAMP-dependent protein kinase in the cGMP-induced phosphorylation of vasodilator-stimulated phosphoprotein and platelet inhibition in humans. Blood. 2003;101:4423-4429
29. Walter U, Gambaryan S. Roles of cGMP/cGMP-dependent protein kinase in platelet activation. Blood. 2004;104:2609
30. Gambaryan S, Geiger J, Schwarz UR, Butt E, Begonja A, Obergfell A, Walter U. Potent inhibition of human platelets by cGMP analogs independent of cGMP-dependent protein kinase. Blood. 2004;103: 2593-2600
31. Marshall SJ, Senis YA, Auger JM, Feil R, Hofmann F, Salmon G, Peterson JT, Burslem F, Watson SP. GPIb-dependent platelet activation is dependent on Src kinases but not MAP kinase or cGMP-dependent kinase. Blood. 2004;103:2601-2609
32. Hubbard GP, Wolffram S, Lovegrove JA, Gibbins JM. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagenstimulated platelet activation pathway in humans. J Thromb Haemost. 2004;2:2138-2145
33. Guerrero JA, Lozano ML, Castillo J, Benavente-García O, Vicente V, Rivera J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J Thromb Haemost. 2005;3:369-376
34. Guerrero JA, Navarro-Nuñez L, Lozano ML, Martínez C, Vicente V, Gibbins JM, Rivera J. Flavonoids inhibit the platelet TxA(2) signalling pathway and antagonize TxA(2) receptors (TP) in platelets and smooth muscle cells. Br J Clin Pharmacol. 2007;64:133-144
35. Freedman JE, Parker C III, Li L, Perlman JA, Frei B, Ivanov V, Deak LR, Iafrati MD, Folts JD. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001;103:2792-2798
36. Matter WF, Brown RF, Vlahos CJ. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem Biophys Res Commun. 1992;186:624-631
37. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248
38. Oak MH, Chataigneau M, Keravis T, Chataigneau T, Beretz A, Andriantsitohaina R, Stoclet JC, Chang SJ, Schini-Kerth VB. Red wine polyphenolic compounds inhibit vascular endothelial growth factor expression in vascular smooth muscle cells by preventing the activation of the p38 mitogen-Activated protein kinase pathway. Arterioscler Thromb Vasc Biol. 2003;23:1001-1007
39. Kobuchi H, Roy S, Sen CK, Nguyen HG, Packer L. Quercetin inhibits inducible ICAM-1 expression in human endothelial cells through the JNK pathway. Am J Physiol. 1999;277(3 pt 1):C403-C411
40. Butt E, Abel K, Krieger M, Palm D, Hoppe V, Hoppe J, Walter U. cAMPand cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem. 1994;269:14509-14517
41. Beavo JA, Brunton LL. Cyclic nucleotide research-still expanding after half a century. Nat Rev Mol Cell Biol. 2002;3:710-718
42. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMPdependent protein kinases and the cardiovascular system: Insights from genetically modified mice. Circ Res. 2003;93:907-916
43. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular and platelet actions of nitric oxide: Confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci U S A. 1996;93:1480-1485
44. Walford G, Loscalzo J. Nitric oxide in vascular biology. J Thromb Haemost. 2003;1:2112-2118
45. Nguyen BL, Saitoh M, Ware JA. Interaction of nitric oxide and cGMP with signal transduction in activated platelets. Am J Physiol. 1991;261(4 pt 2):H1043-H1052
46. Trepakova ES, Cohen RA, Bolotina VM. Nitric oxide inhibits capacitative cation influx in human platelets by promoting sarcoplasmic/endoplasmic reticulum Ca2+-ATPase-dependent refilling of Ca2+ stores. Circ Res. 1999;84:201-209
47. Pigazzi A, Heydrick S, Folli F, Benoit S, Michelson A, Loscalzo J. Nitric oxide inhibits thrombin receptor-Activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem. 1999;274:14368-14375
48. Mendelsohn ME, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-Acetylcysteine. J Biol Chem. 1990;265:19028-19034
49. Horstrup K, Jablonka B, Hönig-Liedl P, Just M, Kochsiek K, Walter U. Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition. Eur J Biochem. 1994;225:21-27
50. Wang GR, Zhu Y, Halushka PV, Lincoln TM, Mendelsohn ME. Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1998;95:4888-4893
51. Jasuja R, Passam FH, Kennedy DR, Kim SH, van Hessem L, Lin L, Bowley SR, Joshi SS, Dilks JR, Furie B, Furie BC, Flaumenhaft R. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest. 2012;122:2104-2113
52. Naseem KM. eNOS, iNOS or no NOS, that is the question! J Thromb Haemost. 2008;6:1373-1375
53. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112:77-86
54. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitricoxide synthase 3 and guanylyl cyclase in platelet activation. J Biol Chem. 2005;280:37430-37438
55. Gambaryan S, Kobsar A, Hartmann S, Birschmann I, Kuhlencordt PJ, Müller-Esterl W, Lohmann SM, Walter U. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost. 2008;6:1376-1384
56. Ozüyaman B, Gödecke A, Küsters S, Kirchhoff E, Scharf RE, Schrader J. Endothelial nitric oxide synthase plays a minor role in inhibition of arterial thrombus formation. Thromb Haemost. 2005;93:1161-1167
57. Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem. 2002;50:5837-5843
58. Cheng Z, Surichan S, Ruparelia K, Arroo R, Boarder MR. Tangeretin and its metabolite 4'-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K. Br J Pharmacol. 2011;162:1781-1791